Tzamal Medical, Duchesnay partner to distribute and sell Diclectin for management of NVP

Duchesnay Inc. and Tzamal Medical Group Ltd today announced that they have signed an agreement whereby Tzamal Medical Group has been granted exclusive rights to distribute and sell throughout the Israeli market the prescription medicine Diclectin^® (doxylamine 10 mg/pyridoxine 10 mg delayed-release tablet) indicated for the management of nausea and vomiting of pregnancy (NVP).

"We are very pleased to partner with Tzamal Medical Group, a successful and trusted industry leader in the field of medical and pharmaceutical specialty products", said Éric Gervais, Executive Vice-President of Duchesnay Inc. "This strategic collaboration represents an important milestone in our endeavor to help pregnant women suffering from nausea and vomiting of pregnancy (NVP). We are excited to enable expectant mothers within the Israeli market to have access to a proven safe and effective pharmacological treatment for NVP."

"Diclectin ®, as a delayed release combination proved its impeccable efficacy and safety in North America / Canada for years and as such recommended as first choice by both the Society Obstetricians and Gynaecologists of Canada (SOGC) and the American College of Obstetricians and Gynaecologists (ACOG)" - said E. Steinberg , CEO of Tzamal BioPharma Ltd, the pharmaceutical arm of Tzamal Medical Ltd -  "and we are confident that the available solid clinical and safety data of the drug will  allow the Israeli MOH to approve it as the first drug to address specifically for NVP, a very important unmet need of the pregnant women up to now".